ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ONBI One Bio Corp (CE)

0.003
0.00 (0.00%)
29 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
One Bio Corp (CE) USOTC:ONBI OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.003 0.00 01:00:00

ONE Bio Announces 132% Year-Over-Year Sales Growth for 2010

22/02/2011 1:00pm

Marketwired


One Bio (CE) (USOTC:ONBI)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more One Bio (CE) Charts.

ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, today announced preliminary unaudited revenues of $51 million for the fiscal year ended December 31, 2010, representing an increase of 132% from $22 million for fiscal 2009.

The increase in sales was primarily due to acquisitions the Company completed during 2009 and new products the Company launched in 2010. Sales of the new products contributed $6.4 million, accounting for 12% of total 2010 revenues. The new products also yielded an average gross margin of approximately 54%.

ONE's Chemical and Herbal Extract ("CHE") division led the Company's product launches, introducing several new products, including Sero®, a house-branded stevia sweetener; Green Tea Extracts, Sarcandra, and Ganoderma Tea.

"These in-demand new products, along with our core products, position ONE for continued and sustainable growth at high margins," stated ONE's CEO, Marius Silvasan. "The new products launched during 2010 and the acquisitions we completed in 2009 were our primary sales growth drivers in 2010. Products launched during the fiscal year also yielded a gross margin above 54%, which is higher than the gross margin yielded by our core products. This was made possible by our strong R&D team, which consistently examines market trends and market data to develop innovative products."

Mr. Silvasan continued, "Just as significant is the impressive performance of our first over-the-counter health beverage, Ganoderma Tea, which we launched during 2010. Sales of this product reached over $5 million in 2010, representing 26% of our nutraceutical sales. This further validates our focus on the development of more OTC products that utilize our raw materials."

About ONE Bio, Corp. ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com), headquartered in Miami, FL, is an innovative company utilizing patented green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region and the Unites States. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE has experienced solid organic growth driven by a robust demand for its products in China, Japan and the United States.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Company Contact: Jeanne Chan Senior VP Tel. +888.676.4445 jchan@onehcorp.com Contact: Investor Relations & Corporate Communications 888-676-4445 ir@onehcorp.com

1 Year One Bio (CE) Chart

1 Year One Bio (CE) Chart

1 Month One Bio (CE) Chart

1 Month One Bio (CE) Chart

Your Recent History

Delayed Upgrade Clock